{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:20:23Z","timestamp":1793067623452,"version":"4.5.0"},"reference-count":214,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1038\/s41591-024-03281-3","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T06:02:28Z","timestamp":1728972148000},"page":"2756-2770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Cell therapy for neurological disorders"],"prefix":"10.1038","volume":"30","author":[{"given":"Soshana P.","family":"Svendsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8696-3446","authenticated-orcid":false,"given":"Clive N.","family":"Svendsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"key":"3281_CR1","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1182\/blood-2008-08-078220","volume":"112","author":"IL Weissman","year":"2008","unstructured":"Weissman, I. L. & Shizuru, J. A. The origins of the identification and isolation of hematopoietic stem cells, and their capability to induce donor-specific transplantation tolerance and treat autoimmune diseases. Blood 112, 3543\u20133553 (2008).","journal-title":"Blood"},{"key":"3281_CR2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","volume":"28","author":"AV Finck","year":"2022","unstructured":"Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G. & June, C. H. Engineered cellular immunotherapies in cancer and beyond. Nat. Med. 28, 678\u2013689 (2022).","journal-title":"Nat. Med."},{"key":"3281_CR3","first-page":"95","volume":"1","author":"HJ Kim","year":"2015","unstructured":"Kim, H. J. et al. Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer\u2019s disease dementia: a phase 1 clinical trial. Alzheimers Dement. 1, 95\u2013102 (2015).","journal-title":"Alzheimers Dement."},{"key":"3281_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s12975-023-01163-3","author":"X Liu","year":"2023","unstructured":"Liu, X. & Jia, X. Neuroprotection of stem cells against ischemic brain injury: from bench to clinic. Transl. Stroke Res. https:\/\/doi.org\/10.1007\/s12975-023-01163-3 (2023).","journal-title":"Transl. Stroke Res."},{"key":"3281_CR5","doi-asserted-by":"publisher","first-page":"e1202","DOI":"10.1212\/WNL.0000000000011450","volume":"96","author":"M Kawabori","year":"2021","unstructured":"Kawabori, M. et al. Cell therapy for chronic TBI: interim analysis of the randomized controlled STEMTRA trial. Neurology 96, e1202\u2013e1214 (2021).","journal-title":"Neurology"},{"key":"3281_CR6","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.3390\/pharmaceutics15112637","volume":"15","author":"H Wu","year":"2023","unstructured":"Wu, H., Fan, Y. & Zhang, M. Advanced progress in the role of adipose-derived mesenchymal stromal\/stem cells in the application of central nervous system disorders. Pharmaceutics 15, 2637 (2023).","journal-title":"Pharmaceutics"},{"key":"3281_CR7","doi-asserted-by":"publisher","first-page":"eaba6884","DOI":"10.1126\/sciadv.aba6884","volume":"6","author":"O Levy","year":"2020","unstructured":"Levy, O. et al. Shattering barriers toward clinically meaningful MSC therapies. Sci. Adv. 6, eaba6884 (2020).","journal-title":"Sci. Adv."},{"key":"3281_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-024-04999-x","author":"X Feng","year":"2024","unstructured":"Feng, X. et al. From stem cells to pancreatic \u03b2-cells: strategies, applications, and potential treatments for diabetes. Mol. Cell. Biochem. https:\/\/doi.org\/10.1007\/s11010-024-04999-x (2024).","journal-title":"Mol. Cell. Biochem."},{"key":"3281_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-02055-5","author":"B Keymeulen","year":"2023","unstructured":"Keymeulen, B. et al. Encapsulated stem cell-derived \u03b2 cells exert glucose control in patients with type 1 diabetes. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-023-02055-5 (2023).","journal-title":"Nat. Biotechnol."},{"key":"3281_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/CRD.0000000000000173","volume":"26","author":"C Ashur","year":"2018","unstructured":"Ashur, C. & Frishman, W. H. Cardiosphere-derived cells and ischemic heart failure. Cardiol. Rev. 26, 8\u201321 (2018).","journal-title":"Cardiol. Rev."},{"key":"3281_CR11","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/s41591-022-01862-8","volume":"28","author":"RN Van Gelder","year":"2022","unstructured":"Van Gelder, R. N. et al. Regenerative and restorative medicine for eye disease. Nat. Med. 28, 1149\u20131156 (2022).","journal-title":"Nat. Med."},{"key":"3281_CR12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/stcltm\/szae004","volume":"13","author":"V Klymenko","year":"2024","unstructured":"Klymenko, V., Gonz\u00e1lez Mart\u00ednez, O. G. & Zarbin, M. Recent progress in retinal pigment epithelium cell-based therapy for retinal disease. Stem Cells Transl. Med. 13, 317\u2013331 (2024).","journal-title":"Stem Cells Transl. Med."},{"key":"3281_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/oxfordjournals.bmb.a011646","volume":"53","author":"SB Dunnett","year":"1997","unstructured":"Dunnett, S. B., Kendall, A. L., Watts, C. & Torres, E. M. Neuronal cell transplantation for Parkinson\u2019s and Huntington\u2019s diseases. Br. Med. Bull. 53, 757\u2013776 (1997).","journal-title":"Br. Med. Bull."},{"key":"3281_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1006\/exnr.1999.7098","volume":"158","author":"MK Carpenter","year":"1999","unstructured":"Carpenter, M. K. et al. In vitro expansion of a multipotent population of human neural progenitor cells. Exp. Neurol. 158, 265\u2013278 (1999).","journal-title":"Exp. Neurol."},{"key":"3281_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1006\/exnr.1999.7237","volume":"161","author":"A Villa","year":"2000","unstructured":"Villa, A., Snyder, E. Y., Vescovi, A. & Mart\u00ednez-Serrano, A. Establishment and properties of a growth factor-dependent, perpetual neural stem cell line from the human CNS. Exp. Neurol. 161, 67\u201384 (2000).","journal-title":"Exp. Neurol."},{"key":"3281_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0165-0270(98)00126-5","volume":"85","author":"CN Svendsen","year":"1998","unstructured":"Svendsen, C. N. et al. A new method for the rapid and long term growth of human neural precursor cells. J. Neurosci. Methods 85, 141\u2013152 (1998).","journal-title":"J. Neurosci. Methods"},{"key":"3281_CR17","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/j.yexcr.2006.03.012","volume":"312","author":"LS Wright","year":"2006","unstructured":"Wright, L. S., Prowse, K. R., Wallace, K., Linskens, M. H. K. & Svendsen, C. N. Human progenitor cells isolated from the developing cortex undergo decreased neurogenesis and eventual senescence following expansion in vitro. Exp. Cell. Res. 312, 2107\u20132120 (2006).","journal-title":"Exp. Cell. Res."},{"key":"3281_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1469-7580.2005.00449.x","volume":"207","author":"R Zietlow","year":"2005","unstructured":"Zietlow, R. et al. The survival of neural precursor cell grafts is influenced by in vitro expansion. J. Anat. 207, 227\u2013240 (2005).","journal-title":"J. Anat."},{"key":"3281_CR19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1126\/science.282.5391.1145","volume":"282","author":"JA Thomson","year":"1998","unstructured":"Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145\u20131147 (1998).","journal-title":"Science"},{"key":"3281_CR20","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1126\/science.1151526","volume":"318","author":"J Yu","year":"2007","unstructured":"Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917\u20131920 (2007).","journal-title":"Science"},{"key":"3281_CR21","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861\u2013872 (2007).","journal-title":"Cell"},{"key":"3281_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1467-8519.2011.01896.x","volume":"27","author":"RKF Fung","year":"2013","unstructured":"Fung, R. K. F. & Kerridge, I. H. Uncertain translation, uncertain benefit and uncertain risk: ethical challenges facing first-in-human trials of induced pluripotent stem cells. Bioethics 27, 89\u201396 (2013).","journal-title":"Bioethics"},{"key":"3281_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.stem.2023.03.017","volume":"30","author":"S Temple","year":"2023","unstructured":"Temple, S. Advancing cell therapy for neurodegenerative diseases. Cell Stem Cell 30, 512\u2013529 (2023).","journal-title":"Cell Stem Cell"},{"key":"3281_CR24","doi-asserted-by":"publisher","first-page":"106041","DOI":"10.1016\/j.parkreldis.2024.106041","volume":"122","author":"E Mulroy","year":"2024","unstructured":"Mulroy, E., Erro, R., Bhatia, K. P. & Hallett, M. Refining the clinical diagnosis of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 122, 106041 (2024).","journal-title":"Parkinsonism Relat. Disord."},{"key":"3281_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF00243848","volume":"65","author":"P Brundin","year":"1986","unstructured":"Brundin, P. et al. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson\u2019s disease. Exp. Brain Res. 65, 235\u2013240 (1986).","journal-title":"Exp. Brain Res."},{"key":"3281_CR26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/298652a0","volume":"298","author":"A Bj\u00f6rklund","year":"1982","unstructured":"Bj\u00f6rklund, A., Stenevi, U., Dunnett, S. B. & Gage, F. H. Cross-species neural grafting in a rat model of Parkinson\u2019s disease. Nature 298, 652\u2013654 (1982).","journal-title":"Nature"},{"key":"3281_CR27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.stem.2017.09.014","volume":"21","author":"RA Barker","year":"2017","unstructured":"Barker, R. A., Parmar, M., Studer, L. & Takahashi, J. Human trials of stem cell-derived dopamine neurons for Parkinson\u2019s disease: dawn of a new era. Cell Stem Cell 21, 569\u2013573 (2017).","journal-title":"Cell Stem Cell"},{"key":"3281_CR28","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.stem.2023.08.014","volume":"30","author":"A Kirkeby","year":"2023","unstructured":"Kirkeby, A. et al. Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson\u2019s disease, STEM-PD. Cell Stem Cell 30, 1299\u20131314 (2023).","journal-title":"Cell Stem Cell"},{"key":"3281_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.stem.2023.11.009","volume":"31","author":"S Park","year":"2024","unstructured":"Park, S. et al. Preclinical and dose-ranging assessment of hESC-derived dopaminergic progenitors for a clinical trial on Parkinson\u2019s disease. Cell Stem Cell 31, 25\u201338 (2024).","journal-title":"Cell Stem Cell"},{"key":"3281_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.stem.2023.12.005","volume":"31","author":"T Foltynie","year":"2024","unstructured":"Foltynie, T. Scaling up GMP-grade dopaminergic cells for Parkinson\u2019s disease. Cell Stem Cell 31, 5\u20136 (2024).","journal-title":"Cell Stem Cell"},{"key":"3281_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.stem.2014.09.017","volume":"15","author":"S Grealish","year":"2014","unstructured":"Grealish, S. et al. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson\u2019s disease. Cell Stem Cell 15, 653\u2013665 (2014).","journal-title":"Cell Stem Cell"},{"key":"3281_CR32","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3727\/096368912X647144","volume":"22","author":"ME Emborg","year":"2013","unstructured":"Emborg, M. E. et al. Intracerebral transplantation of differentiated human embryonic stem cells to hemiparkinsonian monkeys. Cell Transplant. 22, 831\u2013838 (2013).","journal-title":"Cell Transplant."},{"key":"3281_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.stem.2021.01.005","volume":"28","author":"TW Kim","year":"2021","unstructured":"Kim, T. W. et al. Biphasic activation of WNT signaling facilitates the derivation of midbrain dopamine neurons from hESCs for translational use. Cell Stem Cell 28, 343\u2013355 (2021).","journal-title":"Cell Stem Cell"},{"key":"3281_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.stem.2021.01.004","volume":"28","author":"J Piao","year":"2021","unstructured":"Piao, J. et al. Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01. Cell Stem Cell 28, 217\u2013229 (2021).","journal-title":"Cell Stem Cell"},{"key":"3281_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.stem.2021.01.013","volume":"28","author":"J Takahashi","year":"2021","unstructured":"Takahashi, J. Clinical trial for parkinson\u2019s disease gets a green light in the US. Cell Stem Cell 28, 182\u2013183 (2021).","journal-title":"Cell Stem Cell"},{"key":"3281_CR36","unstructured":"BlueRock. BlueRock\u2019s phase I study with bemdaneprocel in patients with Parkinson\u2019s disease meets primary endpoint. https:\/\/www.bluerocktx.com\/bluerocks-phase-i-study-with-bemdaneprocel-in-patients-with-parkinsons-disease-meets-primary-endpoint\/ (2023)."},{"key":"3281_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/bs.pbr.2016.11.011","volume":"230","author":"A Kirkeby","year":"2017","unstructured":"Kirkeby, A., Parmar, M. & Barker, R. A. Strategies for bringing stem cell-derived dopamine neurons to the clinic: a European approach (STEM-PD). Prog. Brain Res. 230, 165\u2013190 (2017).","journal-title":"Prog. Brain Res."},{"key":"3281_CR38","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.stemcr.2018.05.010","volume":"11","author":"Y-K Wang","year":"2018","unstructured":"Wang, Y. -K. et al. Human clinical-grade parthenogenetic ESC-derived dopaminergic neurons recover locomotive defects of nonhuman primate models of Parkinson\u2019s disease. Stem Cell Rep. 11, 171\u2013182 (2018).","journal-title":"Stem Cell Rep."},{"key":"3281_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/srep34478","volume":"6","author":"I Garitaonandia","year":"2016","unstructured":"Garitaonandia, I. et al. Neural stem cell tumorigenicity and biodistribution assessment for phase I clinical trial in parkinson\u2019s disease. Sci. Rep. 6, 34478 (2016).","journal-title":"Sci. Rep."},{"key":"3281_CR40","doi-asserted-by":"publisher","first-page":"1202027","DOI":"10.3389\/fnins.2023.1202027","volume":"17","author":"R Nakamura","year":"2023","unstructured":"Nakamura, R. et al. A defined method for differentiating human iPSCs into midbrain dopaminergic progenitors that safely restore motor deficits in Parkinson\u2019s disease. Front. Neurosci. 17, 1202027 (2023).","journal-title":"Front. Neurosci."},{"key":"3281_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17165-w","volume":"11","author":"D Doi","year":"2020","unstructured":"Doi, D. et al. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson\u2019s disease. Nat. Commun. 11, 3369 (2020).","journal-title":"Nat. Commun."},{"key":"3281_CR42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.reth.2020.06.002","volume":"13","author":"J Takahashi","year":"2020","unstructured":"Takahashi, J. iPS cell-based therapy for Parkinson\u2019s disease: a Kyoto trial. Regen. Ther. 13, 18\u201322 (2020).","journal-title":"Regen. Ther."},{"key":"3281_CR43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.stem.2015.01.018","volume":"16","author":"PJ Hallett","year":"2015","unstructured":"Hallett, P. J. et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson\u2019s disease. Cell Stem Cell 16, 269\u2013274 (2015).","journal-title":"Cell Stem Cell"},{"key":"3281_CR44","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41591-021-01257-1","volume":"27","author":"Y Tao","year":"2021","unstructured":"Tao, Y. et al. Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys. Nat. Med. 27, 632\u2013639 (2021).","journal-title":"Nat. Med."},{"key":"3281_CR45","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","volume":"382","author":"JS Schweitzer","year":"2020","unstructured":"Schweitzer, J. S. et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson\u2019s disease. N. Engl. J. Med. 382, 1926\u20131932 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3281_CR46","unstructured":"Aspen Neuroscience. Aspen Neuroscience announces first patient dosed in first-in-human phase 1\/2a clinical trial of autologous neuronal cell replacement therapy for Parkinson\u2019s disease. https:\/\/aspenneuroscience.com\/aspen-neuroscience-announces-first-patient-dosed-in-first-in-human-phase-1-2a-clinical-trial-of-autologous-neuronal-cell-replacement-therapy-for-parkinsons-disease\/ (2024)."},{"key":"3281_CR47","doi-asserted-by":"publisher","first-page":"R254","DOI":"10.1093\/hmg\/ddab170","volume":"30","author":"JF Gusella","year":"2021","unstructured":"Gusella, J. F., Lee, J. -M. & MacDonald, M. E. Huntington\u2019s disease: nearly four decades of human molecular genetics. Hum. Mol. Genet. 30, R254\u2013R263 (2021).","journal-title":"Hum. Mol. Genet."},{"key":"3281_CR48","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi, S. J. et al. Potential disease-modifying therapies for Huntington\u2019s disease: lessons learned and future opportunities. Lancet Neurol. 21, 645\u2013658 (2022).","journal-title":"Lancet Neurol."},{"key":"3281_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0301-0082(99)00058-1","volume":"61","author":"N Nakao","year":"2000","unstructured":"Nakao, N. & Itakura, T. Fetal tissue transplants in animal models of Huntington\u2019s disease: the effects on damaged neuronal circuitry and behavioral deficits. Prog. Neurobiol. 61, 313\u2013338 (2000).","journal-title":"Prog. Neurobiol."},{"key":"3281_CR50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.stemcr.2017.11.005","volume":"10","author":"JC Reidling","year":"2018","unstructured":"Reidling, J. C. et al. Human neural stem cell transplantation rescues functional deficits in R6\/2 and Q140 huntington\u2019s disease mice. Stem Cell Rep. 10, 58\u201372 (2018).","journal-title":"Stem Cell Rep."},{"key":"3281_CR51","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1016\/j.ymthe.2023.10.003","volume":"31","author":"SM Holley","year":"2023","unstructured":"Holley, S. M. et al. Transplanted human neural stem cells rescue phenotypes in zQ175 Huntington\u2019s disease mice and innervate the striatum. Mol. Ther. 31, 3545\u20133563 (2023).","journal-title":"Mol. Ther."},{"key":"3281_CR52","doi-asserted-by":"publisher","first-page":"e101185","DOI":"10.1371\/journal.pone.0101185","volume":"9","author":"S Mu","year":"2014","unstructured":"Mu, S. et al. Transplantation of induced pluripotent stem cells improves functional recovery in Huntington\u2019s disease rat model. PLoS ONE 9, e101185 (2014).","journal-title":"PLoS ONE"},{"key":"3281_CR53","doi-asserted-by":"publisher","first-page":"e13082","DOI":"10.1111\/cpr.13082","volume":"54","author":"HJ Park","year":"2021","unstructured":"Park, H. J. et al. Human iPSC-derived neural precursor cells differentiate into multiple cell types to delay disease progression following transplantation into YAC128 Huntington\u2019s disease mouse model. Cell Prolif. 54, e13082 (2021).","journal-title":"Cell Prolif."},{"key":"3281_CR54","doi-asserted-by":"publisher","first-page":"937133","DOI":"10.3389\/fnmol.2022.937133","volume":"15","author":"P Goel","year":"2022","unstructured":"Goel, P. et al. Neuronal cell death mechanisms in Alzheimer\u2019s disease: an insight. Front. Mol. Neurosci. 15, 937133 (2022).","journal-title":"Front. Mol. Neurosci."},{"key":"3281_CR55","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1001\/jamaneurol.2015.1807","volume":"72","author":"MH Tuszynski","year":"2015","unstructured":"Tuszynski, M. H. et al. Nerve growth factor gene therapy: activation of neuronal responses in alzheimer disease. JAMA Neurol. 72, 1139\u20131147 (2015).","journal-title":"JAMA Neurol."},{"key":"3281_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33017-6","volume":"8","author":"LM McGinley","year":"2018","unstructured":"McGinley, L. M. et al. Human neural stem cell transplantation improves cognition in a murine model of Alzheimer\u2019s disease. Sci. Rep. 8, 14776 (2018).","journal-title":"Sci. Rep."},{"key":"3281_CR57","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/scrt313","volume":"4","author":"A Tsukamoto","year":"2013","unstructured":"Tsukamoto, A., Uchida, N., Capela, A., Gorba, T. & Huhn, S. Clinical translation of human neural stem cells. Stem Cell Res. Ther. 4, 102 (2013).","journal-title":"Stem Cell Res. Ther."},{"key":"3281_CR58","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/hipo.22405","volume":"25","author":"RR Ager","year":"2015","unstructured":"Ager, R. R. et al. Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer\u2019s disease and neuronal loss. Hippocampus 25, 813\u2013826 (2015).","journal-title":"Hippocampus"},{"key":"3281_CR59","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.stemcr.2016.12.019","volume":"8","author":"SE Marsh","year":"2017","unstructured":"Marsh, S. E. et al. HuCNS-SC human NSCs fail to differentiate, form ectopic clusters, and provide no cognitive benefits in a transgenic model of Alzheimer\u2019s disease. Stem Cell Rep. 8, 235\u2013248 (2017).","journal-title":"Stem Cell Rep."},{"key":"3281_CR60","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/sctm.16-0362","volume":"6","author":"NRS Goldberg","year":"2017","unstructured":"Goldberg, N. R. S. et al. Human neural progenitor transplantation rescues behavior and reduces \u03b1-synuclein in a transgenic model of dementia with Lewy bodies. Stem Cells Transl. Med. 6, 1477\u20131490 (2017).","journal-title":"Stem Cells Transl. Med."},{"key":"3281_CR61","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nbt.2565","volume":"31","author":"Y Liu","year":"2013","unstructured":"Liu, Y. et al. Medial ganglionic eminence-like cells derived from human embryonic stem cells correct learning and memory deficits. Nat. Biotechnol. 31, 440\u2013447 (2013).","journal-title":"Nat. Biotechnol."},{"key":"3281_CR62","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.stemcr.2019.10.012","volume":"13","author":"T Zhang","year":"2019","unstructured":"Zhang, T. et al. Human neural stem cells reinforce hippocampal synaptic network and rescue cognitive deficits in a mouse model of alzheimer\u2019s disease. Stem Cell Rep. 13, 1022\u20131037 (2019).","journal-title":"Stem Cell Rep."},{"key":"3281_CR63","doi-asserted-by":"publisher","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman, O. et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers 3, 17071 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"3281_CR64","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.3390\/ijms25094809","volume":"25","author":"S Cantara","year":"2024","unstructured":"Cantara, S., Simoncelli, G. & Ricci, C. Antisense oligonucleotides (ASOs) in motor neuron diseases: a road to cure in light and shade. Int. J. Mol. Sci. 25, 4809 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"3281_CR65","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1371\/journal.pmed.0040039","volume":"4","author":"J Yan","year":"2007","unstructured":"Yan, J. et al. Extensive neuronal differentiation of human neural stem cell grafts in adult rat spinal cord. PLoS Med. 4, e39 (2007).","journal-title":"PLoS Med."},{"key":"3281_CR66","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1097\/01.tp.0000235532.00920.7a","volume":"82","author":"L Xu","year":"2006","unstructured":"Xu, L. et al. Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation 82, 865\u2013875 (2006).","journal-title":"Transplantation"},{"key":"3281_CR67","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/ana.24113","volume":"75","author":"EL Feldman","year":"2014","unstructured":"Feldman, E. L. et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann. Neurol. 75, 363\u2013373 (2014).","journal-title":"Ann. Neurol."},{"key":"3281_CR68","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1212\/WNL.0000000000002889","volume":"87","author":"JD Glass","year":"2016","unstructured":"Glass, J. D. et al. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials. Neurology 87, 392\u2013400 (2016).","journal-title":"Neurology"},{"key":"3281_CR69","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/acn3.567","volume":"5","author":"SA Goutman","year":"2018","unstructured":"Goutman, S. A. et al. Long-term phase 1\/2 intraspinal stem cell transplantation outcomes in ALS. Ann. Clin. Transl. Neurol. 5, 730\u2013740 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"3281_CR70","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/sctm.18-0154","volume":"8","author":"L Mazzini","year":"2019","unstructured":"Mazzini, L. et al. Results from phase I clinical trial with intraspinal injection of neural stem cells in amyotrophic lateral sclerosis: a long-term outcome. Stem Cells Transl. Med. 8, 887\u2013897 (2019).","journal-title":"Stem Cells Transl. Med."},{"key":"3281_CR71","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1126\/science.7973664","volume":"266","author":"CE Henderson","year":"1994","unstructured":"Henderson, C. E. et al. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science 266, 1062\u20131064 (1994).","journal-title":"Science"},{"key":"3281_CR72","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/nn.2210","volume":"11","author":"AC Lepore","year":"2008","unstructured":"Lepore, A. C. et al. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 11, 1294\u20131301 (2008).","journal-title":"Nat. Neurosci."},{"key":"3281_CR73","doi-asserted-by":"publisher","first-page":"e689","DOI":"10.1371\/journal.pone.0000689","volume":"2","author":"M Suzuki","year":"2007","unstructured":"Suzuki, M. et al. GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE 2, e689 (2007).","journal-title":"PLoS ONE"},{"key":"3281_CR74","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/WNR.0000000000000092","volume":"25","author":"G Gowing","year":"2014","unstructured":"Gowing, G. et al. Glial cell line-derived neurotrophic factor-secreting human neural progenitors show long-term survival, maturation into astrocytes, and no tumor formation following transplantation into the spinal cord of immunocompromised rats. Neuroreport 25, 367\u2013372 (2014).","journal-title":"Neuroreport"},{"key":"3281_CR75","first-page":"51219","volume":"15","author":"BC Shelley","year":"2014","unstructured":"Shelley, B. C., Gowing, G. & Svendsen, C. N. A cGMP-applicable expansion method for aggregates of human neural stem and progenitor cells derived from pluripotent stem cells or fetal brain tissue. J. Vis. Exp. 15, 51219 (2014).","journal-title":"J. Vis. Exp."},{"key":"3281_CR76","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1212\/WNL.0000000000004105","volume":"89","author":"DJ Rushton","year":"2017","unstructured":"Rushton, D. J., Andres, P. L., Allred, P., Baloh, R. H. & Svendsen, C. N. Patients with ALS show highly correlated progression rates in left and right limb muscles. Neurology 89, 196\u2013206 (2017).","journal-title":"Neurology"},{"key":"3281_CR77","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41591-022-01956-3","volume":"28","author":"RH Baloh","year":"2022","unstructured":"Baloh, R. H. et al. Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1\/2a trial. Nat. Med. 28, 1813\u20131822 (2022).","journal-title":"Nat. Med."},{"key":"3281_CR78","doi-asserted-by":"publisher","first-page":"15587","DOI":"10.1523\/JNEUROSCI.2037-14.2014","volume":"34","author":"GM Thomsen","year":"2014","unstructured":"Thomsen, G. M. et al. Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortex. J. Neurosci. 34, 15587\u201315600 (2014).","journal-title":"J. Neurosci."},{"key":"3281_CR79","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.molmed.2022.09.009","volume":"28","author":"H Okano","year":"2022","unstructured":"Okano, H. Transplantation of neural progenitor cells into the human CNS. Trends Mol. Med. 28, 897\u2013899 (2022).","journal-title":"Trends Mol. Med."},{"key":"3281_CR80","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.stemcr.2023.03.016","volume":"18","author":"AH Laperle","year":"2023","unstructured":"Laperle, A. H. et al. Human iPSC-derived neural progenitor cells secreting GDNF provide protection in rodent models of ALS and retinal degeneration. Stem Cell Rep. 18, 1629\u20131642 (2023).","journal-title":"Stem Cell Rep."},{"key":"3281_CR81","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/cells12060971","volume":"12","author":"H Du","year":"2023","unstructured":"Du, H. et al. Induced pluripotent stem cells and their applications in amyotrophic lateral sclerosis. Cells 12, 971 (2023).","journal-title":"Cells"},{"key":"3281_CR82","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/s41591-018-0140-5","volume":"24","author":"K Fujimori","year":"2018","unstructured":"Fujimori, K. et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 24, 1579\u20131589 (2018).","journal-title":"Nat. Med."},{"key":"3281_CR83","doi-asserted-by":"publisher","first-page":"109224","DOI":"10.1016\/j.celrep.2021.109224","volume":"35","author":"X Huang","year":"2021","unstructured":"Huang, X. et al. Human amyotrophic lateral sclerosis excitability phenotype screen: target discovery and validation. Cell Rep. 35, 109224 (2021).","journal-title":"Cell Rep."},{"key":"3281_CR84","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/j.1460-9568.2007.05702.x","volume":"26","author":"V Darsalia","year":"2007","unstructured":"Darsalia, V., Kallur, T. & Kokaia, Z. Survival, migration and neuronal differentiation of human fetal striatal and cortical neural stem cells grafted in stroke-damaged rat striatum. Eur. J. Neurosci. 26, 605\u2013614 (2007).","journal-title":"Eur. J. Neurosci."},{"key":"3281_CR85","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/brain\/awr094","volume":"134","author":"RH Andres","year":"2011","unstructured":"Andres, R. H. et al. Human neural stem cells enhance structural plasticity and axonal transport in the ischaemic brain. Brain 134, 1777\u20131789 (2011).","journal-title":"Brain"},{"key":"3281_CR86","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.nbd.2012.12.006","volume":"52","author":"Y Mine","year":"2013","unstructured":"Mine, Y. et al. Grafted human neural stem cells enhance several steps of endogenous neurogenesis and improve behavioral recovery after middle cerebral artery occlusion in rats. Neurobiol. Dis. 52, 191\u2013203 (2013).","journal-title":"Neurobiol. Dis."},{"key":"3281_CR87","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1089\/scd.2017.0009","volume":"26","author":"JD Sinden","year":"2017","unstructured":"Sinden, J. D., Hicks, C., Stroemer, P., Vishnubhatla, I. & Corteling, R. Human neural stem cell therapy for chronic ischemic stroke: charting progress from laboratory to patients. Stem Cells Dev. 26, 933\u2013947 (2017).","journal-title":"Stem Cells Dev."},{"key":"3281_CR88","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.expneurol.2005.12.011","volume":"199","author":"K Pollock","year":"2006","unstructured":"Pollock, K. et al. A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke. Exp. Neurol. 199, 143\u2013155 (2006).","journal-title":"Exp. Neurol."},{"key":"3281_CR89","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1177\/1545968309335978","volume":"23","author":"P Stroemer","year":"2009","unstructured":"Stroemer, P. et al. The neural stem cell line CTX0E03 promotes behavioral recovery and endogenous neurogenesis after experimental stroke in a dose-dependent fashion. Neurorehabil. Neural Repair 23, 895\u2013909 (2009).","journal-title":"Neurorehabil. Neural Repair"},{"key":"3281_CR90","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0140-6736(16)30513-X","volume":"388","author":"D Kalladka","year":"2016","unstructured":"Kalladka, D. et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase 1, first-in-man study. Lancet 388, 787\u2013796 (2016).","journal-title":"Lancet"},{"key":"3281_CR91","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/jnnp-2019-322515","volume":"91","author":"KW Muir","year":"2020","unstructured":"Muir, K. W. et al. Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2). J. Neurol. Neurosurg. Psychiatry 91, 396\u2013401 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"3281_CR92","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/sctm.18-0220","volume":"8","author":"G Zhang","year":"2019","unstructured":"Zhang, G. et al. Stable intracerebral transplantation of neural stem cells for the treatment of paralysis due to ischemic stroke. Stem Cells Transl. Med. 8, 999\u20131007 (2019).","journal-title":"Stem Cells Transl. Med."},{"key":"3281_CR93","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/jcbfm.2009.219","volume":"30","author":"K Jin","year":"2010","unstructured":"Jin, K. et al. Transplantation of human neural precursor cells in Matrigel scaffolding improves outcome from focal cerebral ischemia after delayed postischemic treatment in rats. J. Cereb. Blood Flow. Metab. 30, 534\u2013544 (2010).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"3281_CR94","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1460-9568.2008.06599.x","volume":"29","author":"AU Hicks","year":"2009","unstructured":"Hicks, A. U. et al. Transplantation of human embryonic stem cell-derived neural precursor cells and enriched environment after cortical stroke in rats: cell survival and functional recovery. Eur. J. Neurosci. 29, 562\u2013574 (2009).","journal-title":"Eur. J. Neurosci."},{"key":"3281_CR95","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s12015-014-9535-y","volume":"10","author":"H-S Kim","year":"2014","unstructured":"Kim, H. -S. et al. PSA-NCAM+ neural precursor cells from human embryonic stem cells promote neural tissue integrity and behavioral performance in a rat stroke model. Stem Cell Rev. Rep. 10, 761\u2013771 (2014).","journal-title":"Stem Cell Rev. Rep."},{"key":"3281_CR96","unstructured":"Wendling, P. Stem cell therapy improves post-stroke motor function. Medscape https:\/\/www.medscape.com\/viewarticle\/stem-cell-therapy-improves-post-stroke-motor-function-2024a10008ve#:~:text=Significant%20gains%20were%20also%20seen,or%20stroke%20volume%2C%20Steinberg%20said (2024)."},{"key":"3281_CR97","doi-asserted-by":"publisher","first-page":"70S","DOI":"10.1177\/1535759720960464","volume":"20","author":"FE Dudek","year":"2020","unstructured":"Dudek, F. E. Loss of GABAergic interneurons in seizure-induced epileptogenesis-two decades later and in a more complex world. Epilepsy Curr. 20, 70S\u201372S (2020).","journal-title":"Epilepsy Curr."},{"key":"3281_CR98","doi-asserted-by":"publisher","first-page":"1142507","DOI":"10.3389\/fncel.2023.1142507","volume":"17","author":"J Franz","year":"2023","unstructured":"Franz, J. et al. Differential vulnerability of neuronal subpopulations of the subiculum in a mouse model for mesial temporal lobe epilepsy. Front. Cell. Neurosci. 17, 1142507 (2023).","journal-title":"Front. Cell. Neurosci."},{"key":"3281_CR99","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1111\/epi.17381","volume":"63","author":"KJ Miller","year":"2022","unstructured":"Miller, K. J. & Fine, A. L. Decision-making in stereotactic epilepsy surgery. Epilepsia 63, 2782\u20132801 (2022).","journal-title":"Epilepsia"},{"key":"3281_CR100","doi-asserted-by":"publisher","first-page":"833293","DOI":"10.3389\/fneur.2022.833293","volume":"13","author":"MTR Pereira Dalio","year":"2022","unstructured":"Pereira Dalio, M. T. R. et al. Long-term outcome of temporal lobe epilepsy surgery in 621 patients with hippocampal sclerosis: clinical and surgical prognostic factors. Front. Neurol. 13, 833293 (2022).","journal-title":"Front. Neurol."},{"key":"3281_CR101","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.nec.2023.08.006","volume":"35","author":"DG Southwell","year":"2024","unstructured":"Southwell, D. G. Interneuron transplantation for drug-resistant epilepsy. Neurosurg. Clin. N. Am. 35, 151\u2013160 (2024).","journal-title":"Neurosurg. Clin. N. Am."},{"key":"3281_CR102","doi-asserted-by":"publisher","first-page":"963689723115896","DOI":"10.1177\/09636897231158967","volume":"32","author":"A Alayli","year":"2023","unstructured":"Alayli, A. et al. Stem cells: recent developments redefining epilepsy therapy. Cell Transplant. 32, 9636897231158968 (2023).","journal-title":"Cell Transplant."},{"key":"3281_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01270-x","volume":"11","author":"A Gonzalez-Ramos","year":"2021","unstructured":"Gonzalez-Ramos, A. et al. Human stem cell-derived GABAergic neurons functionally integrate into human neuronal networks. Sci. Rep. 11, 22050 (2021).","journal-title":"Sci. Rep."},{"key":"3281_CR104","doi-asserted-by":"publisher","first-page":"13243","DOI":"10.3390\/ijms222413243","volume":"22","author":"E Waloschkov\u00e1","year":"2021","unstructured":"Waloschkov\u00e1, E. et al. Human stem cell-derived GABAergic interneurons establish efferent synapses onto host neurons in rat epileptic hippocampus and inhibit spontaneous recurrent seizures. Int. J. Mol. Sci. 22, 13243 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"3281_CR105","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.stem.2023.08.013","volume":"30","author":"M Bershteyn","year":"2023","unstructured":"Bershteyn, M. et al. Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy. Cell Stem Cell 30, 1331\u20131350 (2023).","journal-title":"Cell Stem Cell"},{"key":"3281_CR106","unstructured":"Neurona Therapeutics. Neurona Therapeutics presents positive clinical update from NRTX-1001 cell therapy trial in adults with drug-resistant focal epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting. https:\/\/www.neuronatherapeutics.com\/news\/press-releases\/041524\/ (2024)."},{"key":"3281_CR107","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1073\/pnas.1814185115","volume":"116","author":"D Upadhya","year":"2019","unstructured":"Upadhya, D. et al. Human induced pluripotent stem cell-derived MGE cell grafting after status epilepticus attenuates chronic epilepsy and comorbidities via synaptic integration. Proc. Natl Acad. Sci. USA 116, 287\u2013296 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3281_CR108","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41536-022-00234-7","volume":"7","author":"D Upadhya","year":"2022","unstructured":"Upadhya, D. et al. Grafted hPSC-derived GABA-ergic interneurons regulate seizures and specific cognitive function in temporal lobe epilepsy. NPJ Regen. Med. 7, 38 (2022).","journal-title":"NPJ Regen. Med."},{"key":"3281_CR109","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fnmol.2015.00035","volume":"8","author":"A Alizadeh","year":"2015","unstructured":"Alizadeh, A., Dyck, S. M. & Karimi-Abdolrezaee, S. Myelin damage and repair in pathologic CNS: challenges and prospects. Front. Mol. Neurosci. 8, 35 (2015).","journal-title":"Front. Mol. Neurosci."},{"key":"3281_CR110","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s13577-023-01006-1","volume":"37","author":"MV Christodoulou","year":"2024","unstructured":"Christodoulou, M. V. et al. Cell replacement therapy with stem cells in multiple sclerosis, a systematic review. Hum. Cell 37, 9\u201353 (2024).","journal-title":"Hum. Cell"},{"key":"3281_CR111","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.semcdb.2020.12.004","volume":"116","author":"SA Goldman","year":"2021","unstructured":"Goldman, S. A., Mariani, J. N. & Madsen, P. M. Glial progenitor cell-based repair of the dysmyelinated brain: progression to the clinic. Semin. Cell Dev. Biol. 116, 62\u201370 (2021).","journal-title":"Semin. Cell Dev. Biol."},{"key":"3281_CR112","doi-asserted-by":"publisher","first-page":"107658","DOI":"10.1016\/j.celrep.2020.107658","volume":"31","author":"MS Windrem","year":"2020","unstructured":"Windrem, M. S. et al. Human glial progenitor cells effectively remyelinate the demyelinated adult brain. Cell Rep. 31, 107658 (2020).","journal-title":"Cell Rep."},{"key":"3281_CR113","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41591-022-02097-3","volume":"29","author":"A Genchi","year":"2023","unstructured":"Genchi, A. et al. Neural stem cell transplantation in patients with progressive multiple sclerosis: an open-label, phase 1 study. Nat. Med. 29, 75\u201385 (2023).","journal-title":"Nat. Med."},{"key":"3281_CR114","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.stem.2023.11.001","volume":"30","author":"MA Leone","year":"2023","unstructured":"Leone, M. A. et al. Phase I clinical trial of intracerebroventricular transplantation of allogeneic neural stem cells in people with progressive multiple sclerosis. Cell Stem Cell 30, 1597\u20131609 (2023).","journal-title":"Cell Stem Cell"},{"key":"3281_CR115","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.expneurol.2016.05.010","volume":"283","author":"MJ Osorio","year":"2016","unstructured":"Osorio, M. J. & Goldman, S. A. Glial progenitor cell-based treatment of the childhood leukodystrophies. Exp. Neurol. 283, 476\u2013488 (2016).","journal-title":"Exp. Neurol."},{"key":"3281_CR116","doi-asserted-by":"publisher","first-page":"155ra137","DOI":"10.1126\/scitranslmed.3004373","volume":"4","author":"N Gupta","year":"2012","unstructured":"Gupta, N. et al. Neural stem cell engraftment and myelination in the human brain. Sci. Transl. Med. 4, 155ra137 (2012).","journal-title":"Sci. Transl. Med."},{"key":"3281_CR117","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.stemcr.2019.07.002","volume":"13","author":"N Gupta","year":"2019","unstructured":"Gupta, N. et al. Long-term safety, immunologic response, and imaging outcomes following neural stem cell transplantation for Pelizaeus\u2013Merzbacher disease. Stem Cell Rep. 13, 254\u2013261 (2019).","journal-title":"Stem Cell Rep."},{"key":"3281_CR118","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1523\/JNEUROSCI.0311-05.2005","volume":"25","author":"HS Keirstead","year":"2005","unstructured":"Keirstead, H. S. et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J. Neurosci. 25, 4694\u20134705 (2005).","journal-title":"J. Neurosci."},{"key":"3281_CR119","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.stem.2020.07.007","volume":"27","author":"S Ceto","year":"2020","unstructured":"Ceto, S., Sekiguchi, K. J., Takashima, Y., Nimmerjahn, A. & Tuszynski, M. H. Neural stem cell grafts form extensive synaptic networks that integrate with host circuits after spinal cord injury. Cell Stem Cell 27, 430\u2013440 (2020).","journal-title":"Cell Stem Cell"},{"key":"3281_CR120","doi-asserted-by":"publisher","first-page":"110019","DOI":"10.1016\/j.celrep.2021.110019","volume":"37","author":"M Kawai","year":"2021","unstructured":"Kawai, M. et al. Long-term selective stimulation of transplanted neural stem\/progenitor cells for spinal cord injury improves locomotor function. Cell Rep. 37, 110019 (2021).","journal-title":"Cell Rep."},{"key":"3281_CR121","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3390\/medicina59071235","volume":"59","author":"T Shibata","year":"2023","unstructured":"Shibata, T., Tashiro, S., Nakamura, M., Okano, H. & Nagoshi, N. A review of treatment methods focusing on human induced pluripotent stem cell-derived neural stem\/progenitor cell transplantation for chronic spinal cord injury. Medicina 59, 1235 (2023).","journal-title":"Medicina"},{"key":"3281_CR122","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.stem.2018.05.014","volume":"22","author":"E Curtis","year":"2018","unstructured":"Curtis, E. et al. A first-in-human, phase I study of neural stem cell transplantation for chronic spinal cord injury. Cell Stem Cell 22, 941\u2013950.e6 (2018).","journal-title":"Cell Stem Cell"},{"key":"3281_CR123","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1089\/neu.2018.5843","volume":"36","author":"AD Levi","year":"2019","unstructured":"Levi, A. D. et al. Clinical outcomes from a multi-center study of human neural stem cell transplantation in chronic cervical spinal cord injury. J. Neurotrauma 36, 891\u2013902 (2019).","journal-title":"J. Neurotrauma"},{"key":"3281_CR124","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.stemcr.2017.01.024","volume":"8","author":"S Temple","year":"2017","unstructured":"Temple, S. & Studer, L. Lessons learned from pioneering neural stem cell studies. Stem Cell Rep. 8, 191\u2013193 (2017).","journal-title":"Stem Cell Rep."},{"key":"3281_CR125","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.stemcr.2016.12.018","volume":"8","author":"AJ Anderson","year":"2017","unstructured":"Anderson, A. J., Piltti, K. M., Hooshmand, M. J., Nishi, R. A. & Cummings, B. J. Preclinical efficacy failure of human CNS-derived stem cells for use in the pathway study of cervical spinal cord injury. Stem Cell Rep. 8, 249\u2013263 (2017).","journal-title":"Stem Cell Rep."},{"key":"3281_CR126","doi-asserted-by":"publisher","first-page":"630932","DOI":"10.1155\/2015\/630932","volume":"2015","author":"JC Shin","year":"2015","unstructured":"Shin, J. C. et al. Clinical trial of human fetal brain-derived neural stem\/progenitor cell transplantation in patients with traumatic cervical spinal cord injury. Neural Plast. 2015, 630932 (2015).","journal-title":"Neural Plast."},{"key":"3281_CR127","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/sctm.17-0065","volume":"6","author":"NC Manley","year":"2017","unstructured":"Manley, N. C., Priest, C. A., Denham, J., Wirth, E. D. & Lebkowski, J. S. Human embryonic stem cell-derived oligodendrocyte progenitor cells: preclinical efficacy and safety in cervical spinal cord injury. Stem Cells Transl. Med. 6, 1917\u20131929 (2017).","journal-title":"Stem Cells Transl. Med."},{"key":"3281_CR128","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.5966\/sctm.2014-0147","volume":"3","author":"CT Scott","year":"2014","unstructured":"Scott, C. T. & Magnus, D. Wrongful termination: lessons from the Geron clinical trial. Stem Cells Transl. Med. 3, 1398\u20131401 (2014).","journal-title":"Stem Cells Transl. Med."},{"key":"3281_CR129","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3171\/2021.12.SPINE21622","volume":"37","author":"SL McKenna","year":"2022","unstructured":"McKenna, S. L. et al. Ten-year safety of pluripotent stem cell transplantation in acute thoracic spinal cord injury. J. Neurosurg. Spine 37, 321\u2013330 (2022).","journal-title":"J. Neurosurg. Spine"},{"key":"3281_CR130","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3171\/2022.5.SPINE22167","volume":"37","author":"RG Fessler","year":"2022","unstructured":"Fessler, R. G. et al. A phase 1\/2a dose-escalation study of oligodendrocyte progenitor cells in individuals with subacute cervical spinal cord injury. J. Neurosurg. Spine 37, 812\u2013820 (2022).","journal-title":"J. Neurosurg. Spine"},{"key":"3281_CR131","doi-asserted-by":"publisher","first-page":"e52787","DOI":"10.1371\/journal.pone.0052787","volume":"7","author":"Y Kobayashi","year":"2012","unstructured":"Kobayashi, Y. et al. Pre-evaluated safe human iPSC-derived neural stem cells promote functional recovery after spinal cord injury in common marmoset without tumorigenicity. PLoS ONE 7, e52787 (2012).","journal-title":"PLoS ONE"},{"key":"3281_CR132","doi-asserted-by":"publisher","first-page":"16825","DOI":"10.1073\/pnas.1108077108","volume":"108","author":"S Nori","year":"2011","unstructured":"Nori, S. et al. Grafted human-induced pluripotent stem-cell-derived neurospheres promote motor functional recovery after spinal cord injury in mice. Proc. Natl Acad. Sci. USA 108, 16825\u201316830 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3281_CR133","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00018-017-2676-9","volume":"75","author":"N Nagoshi","year":"2018","unstructured":"Nagoshi, N. & Okano, H. iPSC-derived neural precursor cells: potential for cell transplantation therapy in spinal cord injury. Cell. Mol. Life Sci. 75, 989\u20131000 (2018).","journal-title":"Cell. Mol. Life Sci."},{"key":"3281_CR134","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.reth.2021.08.005","volume":"18","author":"K Sugai","year":"2021","unstructured":"Sugai, K. et al. First-in-human clinical trial of transplantation of iPSC-derived NS\/PCs in subacute complete spinal cord injury: study protocol. Regen. Ther. 18, 321\u2013333 (2021).","journal-title":"Regen. Ther."},{"key":"3281_CR135","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/joim.13469","volume":"292","author":"ST Proulx","year":"2022","unstructured":"Proulx, S. T. & Engelhardt, B. Central nervous system zoning: How brain barriers establish subdivisions for CNS immune privilege and immune surveillance. J. Intern. Med. 292, 47\u201367 (2022).","journal-title":"J. Intern. Med."},{"key":"3281_CR136","doi-asserted-by":"publisher","first-page":"H1","DOI":"10.1530\/VB-19-0033","volume":"2","author":"L Marchetti","year":"2020","unstructured":"Marchetti, L. & Engelhardt, B. Immune cell trafficking across the blood\u2013brain barrier in the absence and presence of neuroinflammation. Vasc. Biol. 2, H1\u2013H18 (2020).","journal-title":"Vasc. Biol."},{"key":"3281_CR137","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJM200103083441002","volume":"344","author":"CR Freed","year":"2001","unstructured":"Freed, C. R. et al. Transplantation of embryonic dopamine neurons for severe Parkinson\u2019s disease. N. Engl. J. Med. 344, 710\u2013719 (2001).","journal-title":"N. Engl. J. Med."},{"key":"3281_CR138","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/096368979700600304","volume":"6","author":"JH Kordower","year":"1997","unstructured":"Kordower, J. H. et al. Fetal grafting for Parkinson\u2019s disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant. 6, 213\u2013219 (1997).","journal-title":"Cell Transplant."},{"key":"3281_CR139","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1371\/journal.pone.0000166","volume":"2","author":"P Krystkowiak","year":"2007","unstructured":"Krystkowiak, P. et al. Alloimmunisation to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington\u2019s disease. PLoS ONE 2, e166 (2007).","journal-title":"PLoS ONE"},{"key":"3281_CR140","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.1073\/pnas.1605245113","volume":"113","author":"W Li","year":"2016","unstructured":"Li, W. et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc. Natl Acad. Sci. USA 113, 6544\u20136549 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3281_CR141","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/sctm.20-0242","volume":"10","author":"BS Jha","year":"2021","unstructured":"Jha, B. S., Farnoodian, M. & Bharti, K. Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. Stem Cells Transl. Med. 10, 198\u2013208 (2021).","journal-title":"Stem Cells Transl. Med."},{"key":"3281_CR142","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nature10135","volume":"474","author":"T Zhao","year":"2011","unstructured":"Zhao, T., Zhang, Z. -N., Rong, Z. & Xu, Y. Immunogenicity of induced pluripotent stem cells. Nature 474, 212\u2013215 (2011).","journal-title":"Nature"},{"key":"3281_CR143","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s13287-023-03576-1","volume":"14","author":"B Kuebler","year":"2023","unstructured":"Kuebler, B. et al. Generation of a bank of clinical-grade, HLA-homozygous iPSC lines with high coverage of the Spanish population. Stem Cell Res. Ther. 14, 366 (2023).","journal-title":"Stem Cell Res. Ther."},{"key":"3281_CR144","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.medj.2022.10.003","volume":"4","author":"S Yoshida","year":"2023","unstructured":"Yoshida, S. et al. A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the Japanese population. Med 4, 51\u201366 (2023).","journal-title":"Med"},{"key":"3281_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00926-5","volume":"8","author":"A Morizane","year":"2017","unstructured":"Morizane, A. et al. MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nat. Commun. 8, 385 (2017).","journal-title":"Nat. Commun."},{"key":"3281_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12324-0","volume":"10","author":"R Aron Badin","year":"2019","unstructured":"Aron Badin, R. et al. MHC matching fails to prevent long-term rejection of iPSC-derived neurons in non-human primates. Nat. Commun. 10, 4357 (2019).","journal-title":"Nat. Commun."},{"key":"3281_CR147","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","volume":"24","author":"H Xu","year":"2019","unstructured":"Xu, H. et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell 24, 566\u2013578 (2019).","journal-title":"Cell Stem Cell"},{"key":"3281_CR148","doi-asserted-by":"publisher","first-page":"10441","DOI":"10.1073\/pnas.1902566116","volume":"116","author":"X Han","year":"2019","unstructured":"Han, X. et al. Generation of hypoimmunogenic human pluripotent stem cells. Proc. Natl Acad. Sci. USA 116, 10441\u201310446 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3281_CR149","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/bs.pmbts.2023.02.014","volume":"199","author":"T-C Sung","year":"2023","unstructured":"Sung, T. -C. et al. Universal and hypoimmunogenic pluripotent stem cells for clinical usage. Prog. Mol. Biol. Transl. Sci. 199, 271\u2013296 (2023).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"3281_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s44222-024-00219-9","author":"A Hotta","year":"2024","unstructured":"Hotta, A., Schrepfer, S. & Nagy, A. Genetically engineered hypoimmunogenic cell therapy. Nat. Rev. Bioeng. https:\/\/doi.org\/10.1038\/s44222-024-00219-9 (2024).","journal-title":"Nat. Rev. Bioeng."},{"key":"3281_CR151","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41587-023-01784-x","volume":"42","author":"X Hu","year":"2024","unstructured":"Hu, X. et al. Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques. Nat. Biotechnol. 42, 413\u2013423 (2024).","journal-title":"Nat. Biotechnol."},{"key":"3281_CR152","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41531-021-00183-w","volume":"7","author":"PE Greene","year":"2021","unstructured":"Greene, P. E. et al. Persistent dyskinesias in patients with fetal tissue transplantation for Parkinson disease. NPJ Parkinsons Dis. 7, 38 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"3281_CR153","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ana.24820","volume":"81","author":"JH Kordower","year":"2017","unstructured":"Kordower, J. H. et al. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann. Neurol. 81, 46\u201357 (2017).","journal-title":"Ann. Neurol."},{"key":"3281_CR154","doi-asserted-by":"publisher","first-page":"38ra46","DOI":"10.1126\/scitranslmed.3000976","volume":"2","author":"M Politis","year":"2010","unstructured":"Politis, M. et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson\u2019s patients with neural transplants. Sci. Transl. Med. 2, 38ra46 (2010).","journal-title":"Sci. Transl. Med."},{"key":"3281_CR155","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/00023210-200620060-00004","volume":"20","author":"CH Williams-Gray","year":"2006","unstructured":"Williams-Gray, C. H., Foltynie, T., Lewis, S. J. G. & Barker, R. A. Cognitive deficits and psychosis in Parkinson\u2019s disease: a review of pathophysiology and therapeutic options. CNS Drugs 20, 477\u2013505 (2006).","journal-title":"CNS Drugs"},{"key":"3281_CR156","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10143-018-1007-4","volume":"42","author":"S Sagar","year":"2019","unstructured":"Sagar, S., Rick, J., Chandra, A., Yagnik, G. & Aghi, M. K. Functional brain mapping: overview of techniques and their application to neurosurgery. Neurosurg. Rev. 42, 639\u2013647 (2019).","journal-title":"Neurosurg. Rev."},{"key":"3281_CR157","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/mt.2014.155","volume":"23","author":"MT Silvestrini","year":"2015","unstructured":"Silvestrini, M. T. et al. Interventional magnetic resonance imaging-guided cell transplantation into the brain with radially branched deployment. Mol. Ther. 23, 119\u2013129 (2015).","journal-title":"Mol. Ther."},{"key":"3281_CR158","doi-asserted-by":"publisher","first-page":"31177","DOI":"10.1073\/pnas.1911444117","volume":"117","author":"J-P Lee","year":"2020","unstructured":"Lee, J. -P. et al. Chemical mutagenesis of a GPCR ligand: detoxifying \u201cinflammo-attraction\u201d to direct therapeutic stem cell migration. Proc. Natl Acad. Sci. USA 117, 31177\u201331188 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3281_CR159","doi-asserted-by":"publisher","first-page":"e2302527","DOI":"10.1002\/advs.202302527","volume":"10","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. Enabling survival of transplanted neural precursor cells in the ischemic brain. Adv. Sci. 10, e2302527 (2023).","journal-title":"Adv. Sci."},{"key":"3281_CR160","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41586-023-06300-4","volume":"619","author":"T-Y Park","year":"2023","unstructured":"Park, T. -Y. et al. Co-transplantation of autologous Treg cells in a cell therapy for Parkinson\u2019s disease. Nature 619, 606\u2013615 (2023).","journal-title":"Nature"},{"key":"3281_CR161","doi-asserted-by":"publisher","first-page":"669449","DOI":"10.3389\/fneur.2021.669449","volume":"12","author":"N Ahmed","year":"2021","unstructured":"Ahmed, N., Gandhi, D., Melhem, E. R. & Frenkel, V. MRI guided focused ultrasound-mediated delivery of therapeutic cells to the brain: a review of the state-of-the-art methodology and future applications. Front. Neurol. 12, 669449 (2021).","journal-title":"Front. Neurol."},{"key":"3281_CR162","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5966\/sctm.2015-0422","volume":"6","author":"JJ Lamanna","year":"2017","unstructured":"Lamanna, J. J. et al. Ferumoxytol labeling of human neural progenitor cells for diagnostic cellular tracking in the porcine spinal cord with magnetic resonance imaging. Stem Cells Transl. Med. 6, 139\u2013150 (2017).","journal-title":"Stem Cells Transl. Med."},{"key":"3281_CR163","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1148\/radiol.2018180449","volume":"289","author":"JWM Bulte","year":"2018","unstructured":"Bulte, J. W. M. & Daldrup-Link, H. E. Clinical tracking of cell transfer and cell transplantation: trials and tribulations. Radiology 289, 604\u2013615 (2018).","journal-title":"Radiology"},{"key":"3281_CR164","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3727\/096368915X688614","volume":"25","author":"K Bernau","year":"2016","unstructured":"Bernau, K. et al. In vivo tracking of human neural progenitor cells in the rat brain using magnetic resonance imaging is not enhanced by ferritin expression. Cell Transplant. 25, 575\u2013592 (2016).","journal-title":"Cell Transplant."},{"key":"3281_CR165","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-017-0369-9","volume":"18","author":"Z Yarjanli","year":"2017","unstructured":"Yarjanli, Z., Ghaedi, K., Esmaeili, A., Rahgozar, S. & Zarrabi, A. Iron oxide nanoparticles may damage to the neural tissue through iron accumulation, oxidative stress, and protein aggregation. BMC Neurosci. 18, 51 (2017).","journal-title":"BMC Neurosci."},{"key":"3281_CR166","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1093\/brain\/awx255","volume":"140","author":"G Cisbani","year":"2017","unstructured":"Cisbani, G. et al. Presence of tau pathology within foetal neural allografts in patients with Huntington\u2019s and Parkinson\u2019s disease. Brain 140, 2982\u20132992 (2017).","journal-title":"Brain"},{"key":"3281_CR167","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1093\/brain\/awz104","volume":"142","author":"CW Olanow","year":"2019","unstructured":"Olanow, C. W., Savolainen, M., Chu, Y., Halliday, G. M. & Kordower, J. H. Temporal evolution of microglia and \u03b1-synuclein accumulation following foetal grafting in Parkinson\u2019s disease. Brain 142, 1690\u20131700 (2019).","journal-title":"Brain"},{"key":"3281_CR168","doi-asserted-by":"publisher","first-page":"106542","DOI":"10.1016\/j.nbd.2024.106542","volume":"198","author":"S Salem","year":"2024","unstructured":"Salem, S. et al. Evidence of mutant huntingtin and tau-related pathology within neuronal grafts in Huntington\u2019s disease cases. Neurobiol. Dis. 198, 106542 (2024).","journal-title":"Neurobiol. Dis."},{"key":"3281_CR169","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-018-0893-8","volume":"18","author":"SL Sison","year":"2018","unstructured":"Sison, S. L., Vermilyea, S. C., Emborg, M. E. & Ebert, A. D. Using patient-derived induced pluripotent stem cells to identify Parkinson\u2019s disease-relevant phenotypes. Curr. Neurol. Neurosci. Rep. 18, 84 (2018).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"3281_CR170","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s11064-019-02781-w","volume":"44","author":"O Zygogianni","year":"2019","unstructured":"Zygogianni, O. et al. In vivo phenotyping of familial Parkinson\u2019s Disease with human induced pluripotent stem cells: a proof-of-concept study. Neurochem. Res. 44, 1475\u20131493 (2019).","journal-title":"Neurochem. Res."},{"key":"3281_CR171","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00401-016-1582-9","volume":"132","author":"I Jeon","year":"2016","unstructured":"Jeon, I. et al. Human-to-mouse prion-like propagation of mutant huntingtin protein. Acta Neuropathol. 132, 577\u2013592 (2016).","journal-title":"Acta Neuropathol."},{"key":"3281_CR172","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.stem.2012.04.026","volume":"11","author":"MC An","year":"2012","unstructured":"An, M. C. et al. Genetic correction of Huntington\u2019s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11, 253\u2013263 (2012).","journal-title":"Cell Stem Cell"},{"key":"3281_CR173","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1200\/EDBK_319783","volume":"41","author":"R Kurzrock","year":"2021","unstructured":"Kurzrock, R. et al. Moving beyond 3+3: the future of clinical trial design. Am. Soc. Clin. Oncol. Educ. Book 41, e133\u2013e144 (2021).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"3281_CR174","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1748-720X.2002.tb00720.x","volume":"30","author":"PA Clark","year":"2002","unstructured":"Clark, P. A. Placebo surgery for Parkinson\u2019s disease: do the benefits outweigh the risks? J. Law Med. Ethics 30, 58\u201368 (2002).","journal-title":"J. Law Med. Ethics"},{"key":"3281_CR175","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.stem.2023.12.004","volume":"31","author":"V Tabar","year":"2024","unstructured":"Tabar, V. & Barker, R. A. Sham surgery for the trialing of cell-based therapies to the CNS may not be necessary. Cell Stem Cell 31, 158\u2013160 (2024).","journal-title":"Cell Stem Cell"},{"key":"3281_CR176","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-3-030-81147-1_4","volume":"1344","author":"RG Lewis","year":"2021","unstructured":"Lewis, R. G., Florio, E., Punzo, D. & Borrelli, E. The brain\u2019s reward system in health and disease. Adv. Exp. Med. Biol. 1344, 57\u201369 (2021).","journal-title":"Adv. Exp. Med. Biol."},{"key":"3281_CR177","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/mds.21894","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Placebo response in Parkinson\u2019s disease: comparisons among 11 trials covering medical and surgical interventions. Mov. Disord. 23, 690\u2013699 (2008).","journal-title":"Mov. Disord."},{"key":"3281_CR178","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1126\/science.1060937","volume":"293","author":"R de la Fuente-Fern\u00e1ndez","year":"2001","unstructured":"de la Fuente-Fern\u00e1ndez, R. et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson\u2019s disease. Science 293, 1164\u20131166 (2001).","journal-title":"Science"},{"key":"3281_CR179","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1089\/apb.2022.0022","volume":"27","author":"D Eisenman","year":"2022","unstructured":"Eisenman, D. & Swindle, S. Food and Drug Administration guidance on design of clinical trials for gene therapy products with potential for genome integration or genome editing and associated long-term follow-up of research subjects. Appl. Biosaf. 27, 201\u2013209 (2022).","journal-title":"Appl. Biosaf."},{"key":"3281_CR180","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4103\/2229-3485.71852","volume":"1","author":"V Suvarna","year":"2010","unstructured":"Suvarna, V. Phase IV of drug development. Perspect. Clin. Res. 1, 57\u201360 (2010).","journal-title":"Perspect. Clin. Res."},{"key":"3281_CR181","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/01.STR.32.7.1598","volume":"32","author":"Stroke Therapy Academic Industry Roundtable II (STAIR-II).","year":"2001","unstructured":"Stroke Therapy Academic Industry Roundtable II (STAIR-II).Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 32, 1598\u20131606 (2001).","journal-title":"Stroke"},{"key":"3281_CR182","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.stemcr.2023.03.005","volume":"18","author":"S Kobold","year":"2023","unstructured":"Kobold, S. et al. History and current status of clinical studies using human pluripotent stem cells. Stem Cell Rep. 18, 1592\u20131598 (2023).","journal-title":"Stem Cell Rep."},{"key":"3281_CR183","first-page":"86","volume":"17","author":"A Mullard","year":"2018","unstructured":"Mullard, A. Pfizer exits neuroscience. Nat. Rev. Drug Discov. 17, 86 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3281_CR184","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41587-023-01798-5","volume":"42","author":"R Vieira","year":"2024","unstructured":"Vieira, R. et al. Young glial progenitor cells competitively replace aged and diseased human glia in the adult chimeric mouse brain. Nat. Biotechnol. 42, 719\u2013730 (2024).","journal-title":"Nat. Biotechnol."},{"key":"3281_CR185","doi-asserted-by":"publisher","first-page":"963689723117100","DOI":"10.1177\/09636897231171001","volume":"32","author":"SR Var","year":"2023","unstructured":"Var, S. R. et al. Transplanting microglia for treating CNS injuries and neurological diseases and disorders, and prospects for generating exogenic microglia. Cell Transplant. 32, 9636897231171000 (2023).","journal-title":"Cell Transplant."},{"key":"3281_CR186","doi-asserted-by":"publisher","first-page":"102128","DOI":"10.1016\/j.gde.2023.102128","volume":"83","author":"K Schaukowitch","year":"2023","unstructured":"Schaukowitch, K., Janas, J. A. & Wernig, M. Insights and applications of direct neuronal reprogramming. Curr. Opin. Genet. Dev. 83, 102128 (2023).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"3281_CR187","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1006\/mcne.1996.0595","volume":"8","author":"TD Palmer","year":"1997","unstructured":"Palmer, T. D., Takahashi, J. & Gage, F. H. The adult rat hippocampus contains primordial neural stem cells. Mol. Cell. Neurosci. 8, 389\u2013404 (1997).","journal-title":"Mol. Cell. Neurosci."},{"key":"3281_CR188","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/S0092-8674(00)80783-7","volume":"97","author":"F Doetsch","year":"1999","unstructured":"Doetsch, F., Caill\u00e9, I., Lim, D. A., Garc\u00eda-Verdugo, J. M. & Alvarez-Buylla, A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97, 703\u2013716 (1999).","journal-title":"Cell"},{"key":"3281_CR189","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1523\/JNEUROSCI.0676-20.2020","volume":"41","author":"SF Sorrells","year":"2021","unstructured":"Sorrells, S. F. et al. Positive controls in adults and children support that very few, if any, new neurons are born in the adult human hippocampus. J. Neurosci. 41, 2554\u20132565 (2021).","journal-title":"J. Neurosci."},{"key":"3281_CR190","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/glia.24471","volume":"72","author":"L Janeckova","year":"2024","unstructured":"Janeckova, L. et al. Astrocyte-like subpopulation of NG2 glia in the adult mouse cortex exhibits characteristics of neural progenitor cells. Glia 72, 245\u2013273 (2024).","journal-title":"Glia"},{"key":"3281_CR191","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/glia.22859","volume":"63","author":"L Dimou","year":"2015","unstructured":"Dimou, L. & Gallo, V. NG2-glia and their functions in the central nervous system. Glia 63, 1429\u20131451 (2015).","journal-title":"Glia"},{"key":"3281_CR192","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s12264-022-01013-6","volume":"39","author":"L Zhang","year":"2023","unstructured":"Zhang, L., Wang, Y., Liu, T., Mao, Y. & Peng, B. Novel microglia-based therapeutic approaches to neurodegenerative disorders. Neurosci. Bull. 39, 491\u2013502 (2023).","journal-title":"Neurosci. Bull."},{"key":"3281_CR193","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ymthe.2019.09.003","volume":"28","author":"Y-C Chen","year":"2020","unstructured":"Chen, Y. -C. et al. A NeuroD1 AAV-based gene therapy for functional brain repair after ischemic injury through in vivo astrocyte-to-neuron conversion. Mol. Ther. 28, 217\u2013234 (2020).","journal-title":"Mol. Ther."},{"key":"3281_CR194","doi-asserted-by":"publisher","first-page":"591883","DOI":"10.3389\/fcell.2020.591883","volume":"8","author":"B Puls","year":"2020","unstructured":"Puls, B. et al. Regeneration of functional neurons after spinal cord injury via in situ NeuroD1-mediated astrocyte-to-neuron conversion. Front. Cell Dev. Biol. 8, 591883 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"3281_CR195","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.stem.2013.12.001","volume":"14","author":"Z Guo","year":"2014","unstructured":"Guo, Z. et al. In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer\u2019s disease model. Cell Stem Cell 14, 188\u2013202 (2014).","journal-title":"Cell Stem Cell"},{"key":"3281_CR196","doi-asserted-by":"publisher","first-page":"104531","DOI":"10.1016\/j.ebiom.2023.104531","volume":"90","author":"Y Xie","year":"2023","unstructured":"Xie, Y., Zhou, J., Wang, L. -L., Zhang, C. -L. & Chen, B. New AAV tools fail to detect Neurod1-mediated neuronal conversion of M\u00fcller glia and astrocytes in vivo. EBioMedicine 90, 104531 (2023).","journal-title":"EBioMedicine"},{"key":"3281_CR197","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.ymthe.2022.01.029","volume":"30","author":"CN Svendsen","year":"2022","unstructured":"Svendsen, C. N. & Sofroniew, M. V. Lineage tracing: the gold standard to claim direct reprogramming in vivo. Mol. Ther. 30, 988\u2013989 (2022).","journal-title":"Mol. Ther."},{"key":"3281_CR198","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.4103\/1673-5374.386400","volume":"19","author":"S Liang","year":"2024","unstructured":"Liang, S., Zhou, J., Yu, X., Lu, S. & Liu, R. Neuronal conversion from glia to replenish the lost neurons. Neural Regen. Res. 19, 1446\u20131453 (2024).","journal-title":"Neural Regen. Res."},{"key":"3281_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33382-x","volume":"13","author":"TM O\u2019Shea","year":"2022","unstructured":"O\u2019Shea, T. M. et al. Lesion environments direct transplanted neural progenitors towards a wound repair astroglial phenotype in mice. Nat. Commun. 13, 5702 (2022).","journal-title":"Nat. Commun."},{"key":"3281_CR200","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archneur.1989.00520420033021","volume":"46","author":"O Lindvall","year":"1989","unstructured":"Lindvall, O. et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson\u2019s disease. A detailed account of methodology and a 6-month follow-up. Arch. Neurol. 46, 615\u2013631 (1989).","journal-title":"Arch. Neurol."},{"key":"3281_CR201","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJM199211263272201","volume":"327","author":"DD Spencer","year":"1992","unstructured":"Spencer, D. D. et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson\u2019s disease. N. Engl. J. Med. 327, 1541\u20131548 (1992).","journal-title":"N. Engl. J. Med."},{"key":"3281_CR202","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/archneur.1990.00530050021007","volume":"47","author":"CR Freed","year":"1990","unstructured":"Freed, C. R. et al. Transplantation of human fetal dopamine cells for Parkinson\u2019s disease. Results at 1 year. Arch. Neurol. 47, 505\u2013512 (1990).","journal-title":"Arch. Neurol."},{"key":"3281_CR203","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJM199504273321702","volume":"332","author":"JH Kordower","year":"1995","unstructured":"Kordower, J. H. et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson\u2019s disease. N. Engl. J. Med. 332, 1118\u20131124 (1995).","journal-title":"N. Engl. J. Med."},{"key":"3281_CR204","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/archneur.56.2.179","volume":"56","author":"RA Hauser","year":"1999","unstructured":"Hauser, R. A. et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch. Neurol. 56, 179\u2013187 (1999).","journal-title":"Arch. Neurol."},{"key":"3281_CR205","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.10720","volume":"54","author":"CW Olanow","year":"2003","unstructured":"Olanow, C. W. et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson\u2019s disease. Ann. Neurol. 54, 403\u2013414 (2003).","journal-title":"Ann. Neurol."},{"key":"3281_CR206","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13311-011-0082-9","volume":"8","author":"CR Freed","year":"2011","unstructured":"Freed, C. R., Zhou, W. & Breeze, R. E. Dopamine cell transplantation for Parkinson\u2019s disease: the importance of controlled clinical trials. Neurotherapeutics 8, 549\u2013561 (2011).","journal-title":"Neurotherapeutics"},{"key":"3281_CR207","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1212\/WNL.58.5.687","volume":"58","author":"RA Hauser","year":"2002","unstructured":"Hauser, R. A. et al. Bilateral human fetal striatal transplantation in Huntington\u2019s disease. Neurology 58, 687\u2013695 (2002).","journal-title":"Neurology"},{"key":"3281_CR208","doi-asserted-by":"publisher","first-page":"13877","DOI":"10.1073\/pnas.97.25.13877","volume":"97","author":"TB Freeman","year":"2000","unstructured":"Freeman, T. B. et al. Transplanted fetal striatum in Huntington\u2019s disease: phenotypic development and lack of pathology. Proc. Natl Acad. Sci. USA 97, 13877\u201313882 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3281_CR209","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1212\/01.wnl.0000264504.14301.f5","volume":"68","author":"CD Keene","year":"2007","unstructured":"Keene, C. D. et al. Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 68, 2093\u20132098 (2007).","journal-title":"Neurology"},{"key":"3281_CR210","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/jnnp-2012-302441","volume":"84","author":"RA Barker","year":"2013","unstructured":"Barker, R. A. et al. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington\u2019s disease. J. Neurol. Neurosurg. Psychiatr. 84, 657\u2013665 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"3281_CR211","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S1474-4422(06)70381-7","volume":"5","author":"A-C Bachoud-L\u00e9vi","year":"2006","unstructured":"Bachoud-L\u00e9vi, A. -C. et al. Effect of fetal neural transplants in patients with Huntington\u2019s disease 6 years after surgery: a long-term follow-up study. Lancet Neurol. 5, 303\u2013309 (2006).","journal-title":"Lancet Neurol."},{"key":"3281_CR212","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/stem.3300","volume":"39","author":"A-C Bachoud-L\u00e9vi","year":"2021","unstructured":"Bachoud-L\u00e9vi, A. -C., Massart, R. & Rosser, A. Cell therapy in Huntington\u2019s disease: taking stock of past studies to move the field forward. Stem Cells 39, 144\u2013155 (2021).","journal-title":"Stem Cells"},{"key":"3281_CR213","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41591-019-0507-2","volume":"25","author":"RA Barker","year":"2019","unstructured":"Barker, R. A. & TRANSEURO consortium Designing stem-cell-based dopamine cell replacement trials for Parkinson\u2019s disease. Nat. Med. 25, 1045\u20131053 (2019).","journal-title":"Nat. Med."},{"key":"3281_CR214","doi-asserted-by":"publisher","first-page":"fcaa230","DOI":"10.1093\/braincomms\/fcaa230","volume":"3","author":"CJG Drew","year":"2021","unstructured":"Drew, C. J. G. et al. Protocol for an open label: phase I trial within a cohort of foetal cell transplants in people with Huntington\u2019s disease. Brain Commun. 3, fcaa230 (2021).","journal-title":"Brain Commun."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03281-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03281-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03281-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T07:05:09Z","timestamp":1729839909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03281-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":214,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["3281"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03281-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.N.S. has patents associated with the production, differentiation and transplantation of iPS cell-derived neural cells and is on the board of Coya Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}